Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
Frohman
E M
EM
Departments of Neurology and Ophthalmology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA. elliot.frohman@utsouthwestern.edu
Havrdova
E
E
Lublin
F
F
Barkhof
F
F
Achiron
A
A
Sharief
M K
MK
Stuve
O
O
Racke
M K
MK
Steinman
L
L
Weiner
H
H
Olek
M
M
Zivadinov
R
R
Corboy
J
J
Raine
C
C
Cutter
G
G
Richert
J
J
Filippi
M
M
D002985:Clinical Protocols; D003711:Demyelinating Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D042241:Early Diagnosis; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000592:standards; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy*; D018579:Patient Selection; D011237:Predictive Value of Tests; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents